english.prescrire.org > Prescrire International > N°173 - July 2016

n°173

July 2016

Issue Contents
Editorial

Free  TB, AIDS: major progress

p.172
The long fight against drug-price speculation, fatalistic attitudes and insufficient funding must go on

Marketing Authorisations

Febuxostat (Adenuric°) and tumour lysis syndrome

p.173-174
More life-threatening adverse events

Tiotropium (Spiriva Respimat°) and unstable asthma

p.174
No noteworthy advantage for preventing exacerbations

Ivermectin cream (Soolantra°) and rosacea

p.175
Continue to use metronidazole

Free  Adalimumab (Humira°) and plaque psoriasis in children

p.176
No better than other immunosuppressants

Nintedanib (Ofev°) and idiopathic pulmonary fibrosis

p.177
More harmful than beneficial

Swiss army knife

p.177

Tigecycline (Tygacil°) and serious infections in children

p.178
A poorly effective and excessively toxic antibiotic

Simvastatin + fenofibrate (Cholib°)

p.178-179
Do not use this combination

INN Common stem: -vastatin

p.179

Adverse Effects

Zidovudine, tenofovir or abacavir?

p.180-183
Different adverse effect profiles

Fluoroquinolones: aortic aneurysm and dissection?

p.184
Discovered after decades of use

Fluoroquinolones: retinal detachment?

p.184
Taking into account risk factors

Reviews

Progestogens and prevention of preterm birth in women at risk

p.185-188
Evaluation results too heterogeneous to justify exposing women and children to these drugs

Outlook

Electronic prescribing: errors due to multiple causes

p.189-193
Interaction between human error and IT design flaws

Free  Student action reduces industry influence in US medical schools

p.194-195
AMSA scorecard

Masthead

Free  Masthead

p.170

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe